Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates

CORAL SPRINGS, FL--(Marketwired - Nov 12, 2014) - Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin® and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.

"We are happy to report that the sales of Nyloxin have been steadily increasing over the past two quarters," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "This is allowing us to begin re-engaging in the drug discovery process; initiating clinical trials in an effort to win eventual drug approval or out-licensing," he continued. "We have made some substantial capital improvements in our laboratory and warehouse facilities, culminating in the current re-certification of the laboratory. With the rollout of Pet Pain-Away this month we expect the sales trend to continue, which should allow us to initiate trials in 2015." he concluded.

Nutra Pharma, through its wholly-owned subsidiary, ReceptoPharm, is currently studying RPI-MN as a treatment for HIV and RPI-78M as a treatment for Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN). In 2011, the company completed a Phase IIb/IIIa study in AMN.

About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. Additionally, the Company markets several drug products for sale for the treatment of pain under the brand Nyloxin®. For additional information about Nutra Pharma, visit: http://www.NutraPharma.com or http://www.Nyloxin.com.

SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's laboratory recertification should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.